Consensus Alvotech

Stocks

ALVO

LU2458332611

Biotechnology & Medical Research

End-of-day quote Nasdaq 04/09/2026			5-day change	1st Jan Change
5.320 ^USD	-1.12%		-0.37%	+3.70%

01/09	Alvotech Shares Rise After FDA Accepts Biologics License Application for AVT80	MT
31/08	Alvotech's Application for Proposed Entyvio Biosimilar Accepted for US FDA Review	MT

Evolution of the Average Target: Alvotech

Evolution of the Target Price: Alvotech

Changes in Analyst Recommendations: Alvotech

d8e0d30d314b.a1ulbTt8fbjjJT-iUt3qB-GutThsn-7xj17fVu6Zt8o.EyP_AlwNONKrRHCXOrDfVtnB2ABf5oW1yjyrM6_1wbMPPJIEYzY80NVnCw~a33bf67da57d0ada53a3228f91aa68e8

Analysts' recommendations: Alvotech

24/08	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says	MT
24/08	BofA Securities Initiates Alvotech at Buy With $7 Price Target	MT
24/03	UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating	MT
24/03	Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating	MT
22/12	Stockholm Bullets - Viscaria Soars on Buy Recommendation	FW
18/11	UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating	MT
05/11	Alvotech Shares Fall After Deutsche Bank Downgrade	MT
04/11	Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14	MT
04/11	Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14	MT
03/11	Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar	DJ
03/11	Top Premarket Decliners	MT
03/11	Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell	MT
03/11	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05	CI
15/25/15	Alvotech Shares Rise After Morgan Stanley Upgrade	MT
14/25/14	Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14	MT
23/25/23	Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says	MT
23/25/23	Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14	MT
21/25/21	UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal	MT
18/25/18	UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating	MT
25/24/25	Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating	MT
24/24/24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
22/24/22	Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	MT
29/24/29	Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	MT
20/23/20	Citigroup Upgrades Alvotech to Neutral From Sell, Adjusts Price Target to $10 From $5	MT
21/23/21	Barclays Initiates Alvotech With Equalweight Rating, Price Target is $10	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALVOTECH					+15.61%
	LONZA GROUP AG					+23.77%
	REVOLUTION MEDICINES, INC.					+20.81%
	IQVIA HOLDINGS INC.					+6.58%
	BEONE MEDICINES AG					+22.95%
	CELLTRION, INC.					+46.49%
	ASCENDIS PHARMA A/S					+16.5%
	MEDPACE HOLDINGS, INC.					-1.53%
	EUROFINS SCIENTIFIC SE					+1.46%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+0.09%
	Average					+15.27%
	Weighted average by Cap.					+18.79%